血清尿酸水平与静脉血栓栓塞复发风险的相关性
这项单中心前瞻性研究纳入280例完成口服抗凝治疗的既往静脉血栓栓塞(VTE)患者,随访约71.1个月,发现血清尿酸(SUA)≥4.38 mg/dL者VTE复发风险约为SUA≤4.37者的三倍,且独立于传统危险因素。
要点
- SUA≥4.38 mg/dL者VTE复发风险较SUA≤4.37者约增三倍(HR 3.04)。
- SUA每增加1 mg/dL,VTE复发调整风险增加30%(HR 1.30)。
- SUA与VTE复发的关联独立于传统危险因素。
核心结论
- 升高的血清尿酸水平与未来VTE复发风险增加相关,且独立于传统危险因素。
研究设计与样本
- 单中心前瞻性研究,纳入280例既往有VTE且已完成口服抗凝治疗期的患者。
- 入组时检测SUA,平均随访71.1±29.2个月,分析SUA与VTE复发的关联。
主要发现
- Kaplan-Meier分析显示SUA最低三分位组(≤4.37 mg/dL)未来VTE复发风险显著更低(P=.003)。
- SUA第二与第三三分位组之间未见差异。
- 多变量Cox回归显示较高SUA三分位组较SUA≤4.37者VTE复发风险约增三倍(HR 3.04,95%CI 1.15–8.05,P=.025)。
- SUA每增加1 mg/dL,VTE复发调整风险增加30%(HR 1.30,95%CI 1.01–1.22,P=.040)。
关键数值与推荐
- SUA三分位切点:I ≤4.37 mg/dL,II 4.38–5.54 mg/dL,III ≥5.55 mg/dL。
- SUA≥4.38 mg/dL者VTE复发风险约为SUA≤4.37者的三倍(HR 3.04,95%CI 1.15–8.05,P=.025)。
- SUA每增加1 mg/dL,VTE复发调整HR 1.30(95%CI 1.01–1.22,P=.040)。
临床怎么用
- 对完成抗凝治疗的VTE患者,可关注SUA水平以辅助评估复发风险。
- SUA≥4.38 mg/dL可能提示VTE复发风险较高,独立于传统危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials Increase in serum uric acid (SUA) levels has been widely associated with higher risk of cardiovascular disease. We investigated the link between SUA levels and the risk of venous thromboembolism (VTE) recurrence. Patients with SUA levels ≥ 4.38 mg/dL showed a three-fold increase in the risk of VTE recurrence. Elevated SUA levels are associated with increased risk of recurrent VTE independently from traditional risk factors. ABSTRACT: Background The link between serum uric acid (SUA) and the risk of cardiovascular disease is well established. However, the impact of SUA levels on the risk of venous thromboembolism (VTE) recurrence is unknown. Objectives To investigate the association between SUA and the risk of VTE recurrence. Patients and Methods We performed a monocenter, prospective study on 280 patients with a previous episode of VTE that completed the oral anticoagulant period. SUA levels at enrollment were correlated with the risk of VTE recurrence (mean follow-up 71.1 ± 29.2 months). Results Patients were stratified according to SUA tertiles distribution at baseline (tertiles cut-off: I ≤ 4.37 mg/dL, II 4.38--5.54 mg/dL, III ≥ 5.55 mg/dL). Fifty episodes of VTE recurrence occurred during the follow-up and Kaplan-Meier survival analysis showed that subjects in the lower tertile of SUA distribution had significantly lower risk of future VTE recurrence (P = .003). No differences were seen among patients belonging to the second and the third tertile of SUA distribution. A multivariate Cox regression analysis showed that higher tertiles of SUA distribution had about three-fold increase in the risk of VTE recurrence as compared to subjects with SUA ≤ 4.37, independently from potential confounders (hazard ratio [HR] 3.04, 95% confidence interval [CI] 1.15--8.05 P = .025). Moreover, we observed that the adjusted hazard of VTE recurrence increased by 30% for each additional unit of SUA (mg/dL; HR 1.30, 95% CI 1.01--1.22, P = .040). Conclusion Elevated SUA levels are associated with increased risk of future VTE recurrence independently from traditional risk factors.
引用
- De Lucchi L, Nardin C, Sponchiado A, et al. Serum uric acid levels and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2020. PMID: 33078502. doi:10.1111/jth.15139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。